title: Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
authors.forename: Thomas
authors.initials: T
authors.lastname: Einarson
authors.forename: Marcio
authors.initials: M
authors.lastname: Machado
authors.forename: John
authors.initials: J
authors.lastname: Walker
authors.forename: Michael
authors.initials: M
authors.lastname: Iskedjian
mesh_terms: D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D011994:Recombinant Proteins; D012107:Research Design
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa